BRAF V600E Mutation as a Predictive Factor of Anti-EGFR Monoclonal Antibodies Therapeutic Effects in Metastatic Colorectal Cancer: a Meta-analysis

2014 ◽  
Vol 29 (4) ◽  
pp. 197-203 ◽  
Author(s):  
Qi Wang ◽  
Wei-guo Hu ◽  
Qi-bin Song ◽  
Jia Wei
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibodies ◽  
Metastatic Colorectal Cancer ◽  
Predictive Factor ◽  
Meta Analysis ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Therapeutic Effects

scholarly journals BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features

2016 ◽  
Vol 17 (8) ◽  
pp. 840-848 ◽  
Author(s):  
Cristin Roma ◽  
Anna Maria Rachiglio ◽  
Raffaella Pasquale ◽  
Francesca Fenizia ◽  
Alessia Iannaccone ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Pathologic Features

BRAF V600E and survival benefit of anti-EGFR monoclonal antibody (mAb) therapy for metastatic colorectal cancer (mCRC): A meta-analysis.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e14605-e14605
Author(s):  
Michael Sorich ◽  
Andrew Rowland ◽  
Mafalda Dias ◽  
Ross Allan McKinnon ◽  
Ganessan Kichenadasse ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibody ◽  
Metastatic Colorectal Cancer ◽  
Survival Benefit ◽  
Meta Analysis ◽  
Braf V600e

First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis

2015 ◽  
Vol 96 (1) ◽  
pp. 156-166 ◽  
Author(s):  
Filippo Pietrantonio ◽  
Chiara Cremolini ◽  
Fausto Petrelli ◽  
Maria Di Bartolomeo ◽  
Fotios Loupakis ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Monoclonal Antibodies ◽  
Metastatic Colorectal Cancer ◽  
Meta Analysis ◽  
Wild Type ◽  
First Line

scholarly journals The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation

2019 ◽  
Vol 11 ◽  
pp. 175883591882029 ◽  
Author(s):  
Seiichiro Mitani ◽  
Hiroya Taniguchi ◽  
Keiji Sugiyama ◽  
Toshiki Masuishi ◽  
Kazunori Honda ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Prognostic Score ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Colorectal Cancer Patients ◽  
Line Chemotherapy

Background: BRAF (v-raf murine sarcoma viral oncogene homolog B1) V600E mutant colorectal cancer is associated with short survival. Recently, clinical trials have been conducted to improve outcomes of second or later lines of chemotherapy. However, there is a paucity of reference data pertaining to outcomes of second-line chemotherapy and prognostic factors that are relevant only to BRAF mutant patients. Patients and methods: We retrospectively reviewed metastatic colorectal cancer patients with BRAF V600E mutation who underwent second-line chemotherapy between January 2007 and March 2017. We evaluated treatment outcomes and performed prognostic analyses. Results: A total of 52 patients were included. The median progression-free survival and overall survival (OS) were 2.5 [95% confidence interval (CI) = 1.91–4.11] and 6.5 (95% CI = 4.30–9.63) months, respectively. Overall response and disease control rates were 7% and 48%, respectively. All the regimens which elicited a partial response included BRAF inhibitors in combination with anti-epidermal growth factor receptor (EGFR) antibodies. Therefore, the overall response was 0% after exclusion of patients treated with study drugs. Multivariate analysis for OS revealed that the Glasgow Prognostic Score (GPS), elevated lactate dehydrogenase, and poor performance status were independent prognostic factors. In particular, survival curves according to the GPS stratified the patients into distinct risk groups. The median OSs in patients with GPS of 0, 1, and 2 were 9.9, 5.0, and 1.9 months, respectively. Conclusions: Outcomes of second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation were extremely poor. GPS may be useful in future clinical trials.

Sign in / Sign up

Export Citation Format

Share Document